Leukocyte differentials predict short-term clinical outcome following antipsychotic treatment in schizophrenia

Biological Psychiatry

Volumn 43, Issue 12, 1998, Pages 887-896

  Zorrilla, Eric P ^a   Cannon, Tyrone D ^a   Kessler, Jason ^a   Gur, Raquel E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Autoantibodies; Granulocytes; Lymphocytes; Positive and negative symptoms; Prognosis; Treatment response

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; FEMALE; GRANULOCYTOSIS; HUMAN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIPSYCHOTIC AGENTS; FEMALE; GRANULOCYTES; HUMANS; LEUKOCYTE COUNT; LEUKOCYTES; LEUKOCYTOSIS; MALE; PHENOTYPE; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0032526656     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00358-2     Document Type: Article

References (82)

1. Addington D., Addington J. Depression, dexamethasone nonsuppression and negative symptoms in schizophrenia. Can J Psychiatry. 35:1990;430-433.
2. Altamura C., Guercetti G., Percudani M. Dexamethasone suppression test in positive and negative schizophrenia. Psychiatry Res. 30:1989;69-75.
3. Amkraut A., Soloman G.F., Allansmith M., McClellan B., Rappaport M. Immunoglobulins and improvement in acute schizophrenic reactions. Arch Gen Psychiatry. 28:1973;673-677.
4. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS). 1984;The University of Iowa, Iowa City.
5. Andreasen N.C. The Scale for the Assessment of Positive Symptoms (SAPS). 1984;The University of Iowa, Iowa City.
6. Andreasen N.C., Flaum M., Swayze V.W.I., Tyrrell G., Arndt S. Positive and negative symptoms in schizophrenia A critical reappraisal . Arch Gen Psychiatry. 47:1990;615-621.
7. Banki C.M., Arato M., Rihmer Z. Neuroendocrine differences among subtypes of schizophrenic disorder? An investigation with the dexamethasone suppression test. Neuropsychobiology. 11:1984;174-177.
8. Bessler H., Levental Z., Karp L., Modai I., Djaldetti M., Weizman A. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol Psychiatry. 38:1995;297-302.
9. Bhatia M.S., Agrawal P., Khurana S.K., Dhar N.K., Malik S.C. Immunoglobulin profile in acute psychiatric disorders. Indian J Med Res. 92:1990;101-104.
10. Bhatia M.S., Dhar N.K., Agrawal P., Khurana S.K., Neena B., Malik S.C. Immunoglobulin profile in schizophrenia. Indian J Med Sci. 46:1992;239-242.
11. Cannon T.D., Eyler Zorrilla L., Shtasel D., et al. Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. Arch Gen Psychiatry. 51:1994;651-661.
12. Carpenter W.T.J., Heinrichs D.W., Wagman A.M.I. Deficit and nondeficit forms of schizophrenia the concept . Am J Psychiatry. 145:1988;575-583.
13. Chengappa K.N., Ganguli R., Yang Z.W., et al. Differences in serum interleukin-6 (IL-6) between healthy dextral and non-dextral subjects. Neurosci Res. 20:1994;185-188.
14. Coryell W., Tsuang D. Hypothalamic-pituitary-adrenal axis hyperactivity and psychosis Recovery during an 8-year follow-up . Am J Psychiatry. 149:1992;1033-1039.
15. Coryell W.H., Zimmerman M. HPA axis hyperactivity and recovery from functional psychoses. Am J Psychiatry. 146:1989;473-477.
16. Crow T.J. Molecular pathology of schizophrenia More than one disease process? Br Med J. 280:1980;66-68.
17. Dewan M.J., Pandurangi A.K., Levy B.F., Boucher M.L., Major L.F. Are schizophrenics with abnormal dexamethasone suppression test results a distinct subgroup? Acta Psychiatr Scand. 72:1985;274-277.
18. Dollfus S., Petit M., Menard J.F. Relationship between depressive and positive symptoms in schizophrenia. J Affective Disorders. 28:1993;61-69.
19. Firer M., Sirota P., Schild K., Elizur A., Slor H. Anticardiolipin antibodies are elevated in drug-free, multiply affected families with schizophrenia. J Clin Immunol. 14:1994;73-78.
20. Galinowski A., Barbouche R., Truffinet P., et al. Natural autoantibodies in schizophrenia. Acta Psychiatr Scand. 85:1992;240-242.
21. Ganguli R., Brar J.S., Chengappa K.N.R., et al. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. Arch Gen Psychiatry. 52:1995;668-672.
22. Ganguli R., Brar J.S., Chengappa K.N.R., Yang Z.W., Nimgaonkar V.L., Rabin B.S. Autoimmunity in schizophrenia A review of recent findings . Ann Med. 25:1993;489-496.
23. Ganguli R., Brar J.S., Solomon W., Chengappa K.N., Rabin B.S. Altered interleukin-2 production in schizophrenia Association between clinical state and autoantibody production . Psychiatry Res. 44:1992;113-123.
24. Ganguli R., Rabin B.S. CD5 positive B-lymphocytes in schizophrenia No alteration in numbers or percentage as compared with control subjects . Psychiatry Res. 48:1993;69-78.
25. Ganguli R., Yang Z., Shurin G., et al. Serum interleukin-6 concentration in schizophrenia elevation associated with duration of illness . Psychiatry Res. 51:1994;1-10.
26. Garyfallos G., Lavrentiadis G., Amoutzias D., Monas K., Manos N. Negative symptoms of schizophrenia and the dexamethasone suppression test. Acta Psychiatr Scand. 88:1993;425-428.
27. Geddes J., Merver G., Frith C.D., MacMillan F., Owens D.G., Johnstone E.C. Prediction of outcome following a first episode of schizophrenia. A follow-up study of Northwick Park first episode study subjects. Br J Psychiatry. 165:1994;664-668.
28. Gur R.E., Mozley P.D., Resnick S.M., et al. Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features. Arch Gen Psychiatry. 52:1995;657-667.
29. Gur R.E., Mozley P.D., Shtasel D.L., et al. Clinical subtypes of schizophrenia Differences in brain and CSF volume . Am J Psychiatry. 151:1994;343-350.
30. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 23:1960;56-62.
31. Hase H.D., Goldberg L.R. Comparative validity of different strategies of constructing personality inventory scales. Psychol Bull. 67:1967;231-248.
32. Jonsson S.A., Jonsson H. Outcome in untreated schizophrenia A search for symptoms and traits with prognostic meaning in patients admitted to a mental hospital in the preneuroleptic era . Acta Psychiatr Scand. 85:1992;313-320.
33. Kaneko M., Yokoyama F., Hoshino Y., et al. Hypothalamic-pituitary-adrenal axis function in chronic schizophrenia association with clinical features . Neuropsychobiology. 25:1992;1-7.
34. Kay S.R., Lindenmayer J.P. Outcome predictors in acute schizophrenia. Prospective significance of background and clinical dimensions. J Nerv Ment Dis. 175:1987;152-160.
35. Kay S.R., Murrill L.M. Predicting outcome of schizophrenia Significance of symptom profiles and outcome dimensions . Comp Psychiatry. 31:1990;91-102.
36. Kirch D.G. Infection and autoimmunity as etiologic factors in schizophrenia A review and reappraisal . Schizophr Bull. 19:1993;355-370.
37. Knight J., Knight A., Ungvari G. Can autoimmune mechanisms account for the genetic predisposition to schizophrenia? Br J Psychiatry. 160:1992;533-540.
38. Koliaskina G.I., Chalenko I.M. The cultured lymphocytes of schizophrenia patients. 1. The effect of phytohemagglutinins on a culture of peripheral blood leukocytes from schizophrenia patients with different types of course. Zh Nevropatol Psikhiatr. 70:1970;1017-1021.
39. Kronfol Z., Turner R., House J.D., Winokur G. Elevated blood neutrophil concentration in mania. J Clin Psychiatry. 47:1986;63-65.
40. Kronfol Z., Turner R., Nasrallah H., Winokur G. Leukocyte regulation in depression and schizophrenia. Psychiatry Res. 13:1984;13-18.
41. Levy-Soussan P., Barbouche R., Poirier M.F., Galinowski A., Loo H., Avrameas S. A preliminary prospective study on natural autoantibodies and the response of untreated schizophrenic patients to neuroleptics. Biol Psychiatry. 35:1994;135-138.
42. Lindenmayer J.P., Grochowski S., Kay S.R. Schizophrenic patients with depression Psychopathological profiles and relationship with negative symptoms . Comp Psychiatry. 32:1991;528-533.
43. Lindenmayer J.P., Kay S.R. Affective impairment in young schizophrenics Its structure, course and prognostic significance . Acta Psychiatr Scand. 75:1987;287-296.
44. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania effects of neuroleptics and mood stabilizers . J Psychiatr Res. 29:1995;141-152.
45. Maes M., Bosmans E., Ranjan R., Vandoolaeghe E., Meltzer H.Y., De Ley M., et al. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia Effects of antipsychotic drugs . Schizophr Res. 21:1996;39-50.
46. Maes M., Meltzer H.Y., Bosmans E. Immune-inflammatory markers in schizophrenia Comparison to normal controls and effects of clozapine . Acta Psychiatr Scand. 89:1994;346-351.
47. Mauri M.C., Vita A., Giobbio G.M., et al. Prediction of response to haloperidol in schizophrenia Neuroendocrine, neuromorphological and clinical variables . Int Clin Psychopharmacol. 9:1994;3-7.
48. McGauley G.A., Aldridge C.R., Fahy T.A., Eastment C. The dexamethasone suppression test and negative symptoms of schizophrenia. Acta Psychiatr Scand. 80:1989;548-553.
49. McGlashan T.H. The prediction of outcome in chronic schizophrenia. IV. The Chestnut Lodge follow-up study. Arch Gen Psychiatry. 43:1986;167-176.
50. Menninger K.A. Reversible schizophrenia. Am J Psychiatry. 1:1922;573-588.
51. Minas I.H., Jackson H.J., Joshua S.D., Burgess P.M. Depression, negative and positive symptoms, and the DST in schizophrenia. Schizophr Res. 3:1990;321-327.
52. Muller N., Hofschuster E., Ackenheil M., Eckstein R. T-cells and psychopathology in schizophrenia Relationship to the outcome of neuroleptic therapy . Acta Psychiatr Scand. 87:1993;66-71.
53. Naidenova N.N., Miryutova T.L., Vasilieva O.A. The interferon system in schizophrenic patients during psychotropic therapy. Zh Nevropatol Psikhiatr. 88:1988;96-100.
54. Newcomer J.W., Faustman W.O., Whiteford H.A., Moses J.J., Czernansky J.G. Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenic patients. Biol Psychiatry. 29:1991;855-864.
55. Norman R.M., Malla A.K. Dysphoric mood and symptomatology in schizophrenia. Psychol Med. 21:1991;897-903.
56. Norman R.M., Malla A.K. Correlations over time between dysphoric mood and symptomatology in schizophrenia. Comp Psychiatry. 35:1994;34-38.
57. Noy S., Achiron A., Laor N. Schizophrenia and autoimmunity - A possible etiological mechanism? Neuropsychobiology. 30:1994;157-159.
58. Nunally J.C. Psychometric Theory. 1967;McGraw Hill, New York.
59. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol Rep. 10:1963;799-812.
60. Pollmacher T., Hinze-Selch D., Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol. 16:1996;403-409.
61. Pollmacher T., Hinze-Selch D., Mullington J., Holsboer F. Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors. Arch Gen Psychiatry. 52:1995;877-878.
62. Potapova V.A., Trubnikov V.I. Clinico-immunologic correlations in schizophrenia of various courses (on a B-lymphocyte model). Zh Nevropatol Psikhiatr. 87:1987;727-732.
63. Pulkkinen E., Soininvaara O. Immunoglobulins in schizophrenics and prediction of need for hospital care. Acta Psychiatr Scand. 72:1985;133-138.
64. Rapaport M.H., Torrey E.F., Mcallister C.G., Nelson D.L., Pickar D., Paul S.M. Increased serum-soluble interleukin-2 receptors in schizophrenic monozygotic twins. Eur Arch Psychiatry Clin Neurosci. 243:1993;7-10.
65. SAS/STAT User's Guide. 1988;SAS Institute, Cary, NC.
66. Sekirina T.P., Voronkova T.L., Tsutsulkovskaya M.Y., Abramova L.I. The change of the interleukin-2 production by peripheral blood lymphocytes of schizophrenic patients. Zh Nevropatol Psikhiatr. 89:1989;95-97.
67. Semenov S.F., Glebov V.S. On a study of autoimmune processes connected with pathology of the brain at various stages of the course of schizophrenia. Zh Nevropatol Psikhiatr. 69:1969;87-92.
68. Shintani F., Kanba S., Maruo N., et al. Serum interleukin-6 in schizophrenic patients. Life Sci. 49:1991;661-664.
69. Shtasel D.L., Gur R.E., Mozley P.D., et al. Volunteers for biomedical research. Recruitment and screening of normal controls. Arch Gen Psychiatry. 48:1991;1022-1025.
70. Sirota P., Firer M., Schildi K., et al. Increased anti-Sm antibodies in schizophrenic patients and their families. Prog Neuro Psychopharmacol Biol Psychiatry. 17:1993;793-800.
71. Sirota P., Firer M.A., Schild K., et al. Autoantibodies to DNA in multicase families with schizophrenia. Biol Psychiatry. 33:1993;450-455.
72. Sirota P., Schild K., Elizur A., Dialdetti M., Fishman P. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog Neuro Psychopharmacol. 19:1995;75-83.
73. Spitzer R.L., Williams J.B., Gibbon M. Instruction Manual for the Structured Clinical Interview for DSM-III-R (SCID). 1987;Biometrics Research Department, New York State Psychiatric Institute, New York.
74. Steinmeyer E.M., Marneros A., Deister A., Rohde A., Junemann H. Long-term outcome of schizoaffective and schizophrenic disorders A comparative study. II. Causal-analytical investigations . Eur Arch Psychiatry Neurol Sci. 238:1989;126-134.
75. Stern R.G., Kahn R., Davidson M. Predictors of response to neuroleptic treatment in schizophrenia. Psychiatr Clin North Am. 16:1993;313-338.
76. Szymanski S., Cannon T.D., Gallacher F., Erwin R., Gur R.E. The course of treatment response in first-episode and chronic schizophrenia. Am J Psychiatry. 153:1996;519-525.
77. Tandon R., Mazzara C., DeQuardo J., et al. Dexamethasone suppression test in schizophrenia Relationship to symptomatology, ventricular enlargement, and outcome . Biol Psychiatry. 29:1991;953-964.
78. Tsuang M.T., Lyons M.J., Faraone S.V. Heterogeneity of schizophrenia. Conceptual models and analytic strategies. Br J Psychiatry. 156:1990;17-26.
79. Verghese A., John J.K., Rajkumar S., Richard J., Sethi B.B., Trivedi J.K. Factors associated with the course and outcome of schizophrenia in India. Results of a two-year multicentre follow-up study. Br J Psychiatry. 154:1989;499-503.
80. Winokur G., Tsuang M. Paranoid versus nonparanoid schizophrenia Definition and association . Perris C., Struwe G., Jannson G. Proceedings, Third World Congress of Biological Psychiatry. 1981;761-765 Elsevier/North-Holland, Amsterdam.
81. Wright P., Gill M., Murray R.M. Schizophrenia Genetics and the maternal immune response to viral infection . Am J Med Gen. 48:1993;40-46.
82. Zorrilla E.P., Cannon T.D., Gur R.E., Kessler J. Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings Markers of vulnerability or disease? Biol Psychiatry. 40:1996;825-833.